RSS   Newsletter   Contact   Advertise with us
Post Online Media

WAVE Life Sciences names Keith Regnante as CFO

WAVE Life SciencesWAVE Life Sciences Ltd., a genetic medicines company, announced that it has appointed Keith Regnante as the company’s chief financial officer.
Article continues below

READ MORE ParagonRx: Ellen M. Derrico chief marketing executive

Mr. Regnante joins WAVE with significant financial experience in leadership roles at life sciences companies.

Prior to joining WAVE, he was a Vice President of Finance at Shire where he oversaw finance for R&D, a global organization.

Prior to Shire, Mr. Regnante held a number of positions of increasing responsibility at Biogen, including leading the finance teams for Corporate Finance, R&D, and Business Development.

At Biogen, in addition to serving on the Investor Relations team, he served on teams that closed several significant, high-profile transactions, including the company’s merger with IDEC and its in-licensing and eventual acquisitions of the company’s multiple sclerosis drugs, Tysabri And Tecfidera.

Earlier in his career, Mr. Regnante was a Consultant with The Boston Consulting Group.

He received his MBA from the MIT Sloan School of Management and is a Phi Beta Kappa graduate of Tufts University with a BA in Economics.

 LATEST MOVES FROM Massachusetts 


We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy